Author

Youngil Koh

OpenAlex ID: A5152387651

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials

2026 · Ashutosh D. Wechalekar, Angela Dispenzieri, et al. · Journal of Clinical Oncology · 2

PA-031 Analysis of Subsequent T-Cell–Redirecting Therapies (TCRTs) After Treatment with Belantamab Mafodotin in DREAMM-7 (D7) and DREAMM-8 (D8)

2026 · Roman Hájek, Olaposi Yomade, et al. · Clinical Lymphoma Myeloma & Leukemia

PA-350 Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (D) ± Pomalidomide (P) vs D Plus P and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3

2026 · Peter M. Voorhees, Roberto Mina, et al. · Clinical Lymphoma Myeloma & Leukemia

OA-52 Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/Refractory Multiple Myeloma Patients (MELT-MM): Updated Results From Part 1

2026 · Ja Min Byun, Hyunsoo Cho, et al. · Clinical Lymphoma Myeloma & Leukemia

OA-20 DREAMM-9 Patient-Reported Vision-Related Function with Extended Belantamab Mafodotin Dosing Intervals with Bortezomib, Lenalidomide, Dexamethasone (BVRd) in Transplant Ineligible Multiple Myeloma

2026 · Saad Z. Usmani, Michał Mielnik, et al. · Clinical Lymphoma Myeloma & Leukemia

OA-38 Long-Term Outcomes With Sustained Minimal Residual Disease (MRD) Negativity in Belantamab Mafodotin–Treated Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): An Update From DREAMM-8

2026 · Suzanne Trudel, Güldane Cengiz-Seval, et al. · Clinical Lymphoma Myeloma & Leukemia

PA-343 PFS2 Outcomes in DREAMM-8: Belantamab Mafodotin (Belamaf)-Pomalidomide-Dexamethasone (BPd) vs Pomalidomide-Bortezomib-Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

2026 · Güldane Cengiz-Seval, Sosana Delimpasi, et al. · Clinical Lymphoma Myeloma & Leukemia

PA-266 Integrative Whole-Genome and Transcriptome Sequencing Reveals a Distinct Multiple Myeloma Subtype Characterized by Somatic Hypermutation Signatures

2026 · Sheehyun Kim, Hyundong Yoon, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 8

Citation count: 2

H-index: 1

I10-index: